
Sign up to save your podcasts
Or


How does the new Alzheimer's treatment drug affect our search for a cure?
In the 90s, Alzheimer's researchers were full of optimism that they would find a cure for the disease. Genetic studies all pointed to one culprit—hard clumps of protein, called amyloid, that litter the brains of people with the disease. (Scott Small, MD, Columbia Medicine)
More than thirty years later, we're still looking for a cure, a treatment, or even prevention. Much of the research is still focusing on amyloid and tau proteins, whose malformation are classic characteristics of Alzheimer's disease. But other factors likely play a role, including vascular health, inflammation, lifestyle, and possibly even viral causes. (Healthline Rachel Barclay)
With the latest announcement of Biogen's drug, there is hope and controversy. There is not much evidence that it will work on most people with Alzheimer's; it needs to be started early in the disease and the cost is staggering. At this time, it appears the drug will only be made available to those patients in the earliest stages of the disease.
I've gathered many opinions on this topic. Understandably, there are various them, but the underlying argument is this is only the first step.
Edward Park of NeuroReserve thinks we'll end up with a drug and lifestyle cocktail. My guests in this episode are hopeful as well.
Transcript
Related Episodes:
Could Cannabis be a Cure for Alzheimer’s?
A Ray of Hope? Stabilizing Cognitive Decline
SURVEY!! Share Your Opinion & Get A Chance at the Gift Basket
NeuroReserve – Helping Our Brainspan Match our Lifespan
NeuroReserve – Helping Our Brainspan Match our Lifespan
Facebook Instagram Twitter
Subscribe to our YouTube channel.
There you can see me in “action” and watch the bonus videos I share.
Want to learn from Jennifer in person (or virtually)? Wherever you'd like a training session, Jen is available. Contact her at [email protected]
By Alzheimer's CaregiversHow does the new Alzheimer's treatment drug affect our search for a cure?
In the 90s, Alzheimer's researchers were full of optimism that they would find a cure for the disease. Genetic studies all pointed to one culprit—hard clumps of protein, called amyloid, that litter the brains of people with the disease. (Scott Small, MD, Columbia Medicine)
More than thirty years later, we're still looking for a cure, a treatment, or even prevention. Much of the research is still focusing on amyloid and tau proteins, whose malformation are classic characteristics of Alzheimer's disease. But other factors likely play a role, including vascular health, inflammation, lifestyle, and possibly even viral causes. (Healthline Rachel Barclay)
With the latest announcement of Biogen's drug, there is hope and controversy. There is not much evidence that it will work on most people with Alzheimer's; it needs to be started early in the disease and the cost is staggering. At this time, it appears the drug will only be made available to those patients in the earliest stages of the disease.
I've gathered many opinions on this topic. Understandably, there are various them, but the underlying argument is this is only the first step.
Edward Park of NeuroReserve thinks we'll end up with a drug and lifestyle cocktail. My guests in this episode are hopeful as well.
Transcript
Related Episodes:
Could Cannabis be a Cure for Alzheimer’s?
A Ray of Hope? Stabilizing Cognitive Decline
SURVEY!! Share Your Opinion & Get A Chance at the Gift Basket
NeuroReserve – Helping Our Brainspan Match our Lifespan
NeuroReserve – Helping Our Brainspan Match our Lifespan
Facebook Instagram Twitter
Subscribe to our YouTube channel.
There you can see me in “action” and watch the bonus videos I share.
Want to learn from Jennifer in person (or virtually)? Wherever you'd like a training session, Jen is available. Contact her at [email protected]